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The p53 tumor suppressor coordinates a series of
antiproliferative responses that restrict the expan-
sion of malignant cells, and as a consequence, p53
is lost or mutated in the majority of human cancers.
Here, we show that p53 restricts expression of the
stem and progenitor-cell-associated protein nestin
in an Sp1/3 transcription-factor-dependent manner
and that Nestin is required for tumor initiation in vivo.
Moreover, loss of p53 facilitates dedifferentiation
of mature hepatocytes into nestin-positive progeni-
tor-like cells, which are poised to differentiate into
hepatocellular carcinomas (HCCs) or cholangiocarci-
nomas (CCs) in response to lineage-specific muta-
tions that target Wnt and Notch signaling, respec-
tively. Many human HCCs and CCs show elevated
nestin expression, which correlates with p53 loss of
function and is associated with decreased patient
survival. Therefore, transcriptional repression of
Nestin by p53 restricts cellular plasticity and tumori-
genesis in liver cancer.
INTRODUCTION
p53 mutations occur in a wide range of human cancers and
are often associated with aggressive tumor behavior and poor
patient prognosis (Spike and Wahl, 2011). Wild-type p53 is
activated by DNA damage and various forms of oncogenicstress, during which it induces genes that promote cell-cycle
blockade, apoptosis, senescence, differentiation, and/or auto-
phagy—various aspects of cell metabolism (Vousden and
Lane, 2007)—and can even suppress epigenetic reprogramming
of differentiated cells into induced pluripotent stem (IPS) cells
(Hong et al., 2009; Kawamura et al., 2009; Mario´n et al., 2009).
In addition to its cell-autonomous activities, p53 can promote
the secretion of a variety of factors that influence the tissue
microenvironment in a non-cell-autonomous manner (Lujambio
et al., 2013). Which of these p53 activities is most relevant for
its tumor suppressor role has been widely debated and is likely
context dependent (Kenzelmann Broz and Attardi, 2010).
p53 promotes transcriptional activation through the recruit-
ment of chromatin-modifying proteins to the promoters of genes
with p53 response elements, and indeed, key p53 target genes
contribute to specific effector functions (Vousden and Prives,
2009). p53 can also repress gene expression through mecha-
nisms that are less well understood. p53 can directly repress
transcription by binding p53 response elements in, for example,
the Nanog or CD44 promoters (Godar et al., 2008; Lin et al.,
2005) or indirectly either by inducing genes such as p21, E2F7,
and miR-34 that act through transcriptional or posttranscrip-
tional mechanisms or by antagonizing the basal transcription
machinery and/or transcriptional activators, such as Sp1 and
ETS1 (Ho and Benchimol, 2003). Regardless, the contribution
of this p53 property to tumor suppression is not clear.
p53 mutations are common in primary liver cancers, which
represent the fifth-most frequent tumor type worldwide (Hussain
et al., 2007). These tumors present as either hepatocellular
carcinoma (HCC) or intrahepatic cholangiocarcinoma (CC) and
can easily be distinguished histologically and by assessingCell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc. 579
expression of lineage-specific markers. HCC typically consists
of polygonal cells growing in a solid-trabecular growth pattern,
whereas CC often displays a ductal morphology with a substan-
tial stromal reaction. Although themutational profiles of HCC and
CC are distinct, p53mutations occur in both tumor types and are
associated with a particularly poor prognosis (Hussain et al.,
2007; Nault and Zucman-Rossi, 2011). Studies in mouse models
indicate that p53 inactivation is required for the maintenance of
murine liver carcinomas in vivo (Xue et al., 2007). Still, how p53
acts to limit the development of primary liver cancers remains
poorly understood.
Though it is commonly assumed that HCC and CC arise
through malignant transformation of resident hepatocytes and
cholangiocytes, respectively, the cell of origin of each disease
is controversial. For example, some studies suggest that cholan-
giocarcinoma can arise through transdifferentiation of adult he-
patocytes to cholangiocytes (Fan et al., 2012; Sekiya and Suzuki,
2012), whereas others imply that each tumor type can arise from
bi-potential progenitor cells residing in the adult liver (Roskams,
2006). Consistent with the latter view, rare liver tumors show a
mixed HCC/CC histopathology.
The class IV intermediate filament protein Nestin has been
identified as a marker of bi-potential liver progenitor cells (oval
cells) that reside in the adult liver and expand upon chronic liver
damage (Gleiberman et al., 2005). Nestin is highly expressed in
the mammalian brain and is frequently used as a marker of
neuronal stem cells (Mignone et al., 2004). In glioma, Nestin-
positive cells are crucial for tumor initiation and maintenance
and mark a stem-cell-like population that is necessary to propa-
gate disease (Chen et al., 2012). Here, we show that p53 can
repress Nestin through an indirect mechanism that restricts
tumorigenesis by limiting cellular plasticity and the expansion
of progenitor-like populations in response to oncogenic stress.
Consequently, p53 loss, together with lineage-specific lesions,
enables the emergence of either HCC or CC with progenitor-
like properties that, in patients, are associated with reduced
survival. Our results suggest that the ability of p53 to restrict
the ‘‘reprogramming’’ of differentiated cells into a more pluripo-
tent state contributes to its tumor suppressive role.
RESULTS
p53 Deletion Leads to Mixed Lineage Tumors with High
Nestin Expression
Conditional p53 deletion in the murine liver (using the albumin
promoter combined with a-fetoprotein enhancer [Alfp-cre]) pro-
duces tumors with a mixed HCC/CC histology (Katz et al., 2012)
(Figure 1A). To determine whether these tumors express the pro-
genitor cell marker nestin, we performed immunostaining with an
antibody specifically recognizing the murine Nestin protein.
Surprisingly, high Nestin expression was identified in both the
HCC and the CC components (Figure 1B). Moreover, some Nes-
tin-positive cells were identified in adjacent peritumoral tissue
(Figure 1C), indicating expansion of noncancerous Nestin-posi-
tive cells. By contrast, chemically induced liver tumors produced
by the carcinogen diethylnitrosamine (DEN), which rarely contain
p53mutations (Rumsby et al., 1994), did not express Nestin (Fig-
ure 1D and 1E). Similarly, Nestin mRNA levels were significantly580 Cell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc.higher in p53 null mixed HCC/CC tumors compared to DEN-
induced HCCs (Figure 1F). Thus, liver-specific p53 deletion trig-
gers the formation of bi-lineage liver tumors with high Nestin
expression.
Nestin Levels are High in Human Tumors, where They
Correlate with Poor Patient Prognosis
As a first step toward understanding factors that influenceNestin
expression in liver cancers, we examined Nestin expression in
human liver tumor cell lines using the cancer cell line encyclo-
pedia database. As observed above, cell lines with p53mutation
or genomic loss at the p53 locus show higher Nestin mRNA
levels than those with wild-type p53 (Figure 2A). These results
were confirmed by nestin IHC on 88 primary HCCs with different
etiology (Table S1 available online) and 47 primary human CCs
(Tables S2 and S3). Hence, 17% of the HCCs and 40% of the
CCs exhibited Nestin-positive tumor cells (Figures 2B and
S1A). In contrast, Nestin protein was not expressed in hepato-
cytes of healthy livers and could only be detected in endothelial
cells of blood vessels (Figure 2B). Additionally, Nestin mRNA
levels were significantly higher in HCCs and CCs compared to
surrounding liver tissue (data not shown and Figure S1B). We
also analyzed a small number of human tumors with mixed
HCC/CC histopathology and noted a trend for higher Nestin
expression in those classified with ‘‘stem cell features’’ (2/3)
compared to those with classical HCC/CC histopathology (1/5)
(Figure S1D). Importantly, patients harboring tumors with high
Nestin levels displayed a much worse clinical outcome, with a
median survival of 10 months compared to 29 months for pa-
tients with nestin-negative tumors (Figure 2C). Therefore, like
p53 mutations, Nestin is overexpressed in a subset of all liver
cancer types, where it is associated with poor patient prognosis.
We next compared p53 status as assessed by array-based
CGH and/or sequencing of p53 exons 5–8 to nestin expression,
as determined from publicly available transcriptional profiling
data (Neumann et al., 2012). Nestin levels were significantly
higher in HCC samples that displayed p53mutations or reduced
copy number at the p53 locus (Figures 2D, 2E, and S2C). One
particularly informative HCC sample harbored a single Nestin-
positive nodule in an otherwise multifocal tumor (Figure 2F).
Remarkably, DNA sequencing of microdissected tissue revealed
a p53 S249A mutation in the Nestin-positive nodule, whereas all
of the Nestin-negative nodules harbored wild-type p53 (Fig-
ure 2F). These studies support a direct relationship between
loss of p53 and Nestin expression in human liver cancer.
p53 Represses Nestin Transcription
We next investigated the molecular basis underlying the rela-
tionship between p53 status and nestin expression in the liver.
To report Nestin transcription, we used a transgenic mouse in
which activation of the Nestin promoter drives expression of
green fluorescent protein (GFP) (Gleiberman et al., 2005). Anal-
ysis of adult liver tissues revealed GFP expression limited to
individual cells within the interlobular bile duct and the canal
of Hering (Figure S2A)—the suspected location of the liver
progenitor cell niche in the adult (Fellous et al., 2009). Immuno-
fluorescence staining indicated that expression of the liver
progenitor cell markers A6 and EpCAM overlapped with the
Figure 1. Liver-Specific p53 Deletion Leads to Mixed HCC/CCs with High Nestin Expression
(A) H/E sections from liver tumors of Alfp-Cre p53 fl/fl mice. HCC tumor part and CC tumor part are indicated. Scale bar, 50 mm.
(B) Immunohistochemical staining for nestin in HCC and CC tumor regions. Scale bars, 100 mm.
(C) Nestin immunohistochemistry of peritumoral regions. Scale bar, 100 mm.
(D) H/E and nestin-IHC of DEN-induced tumors. Scale bars, 100 mm.
(E) Quantification of nestin expression in Alfp-Cre p53 fl/fl tumors and DEN-induced tumors.
(F) Quantitative PCR analysis of Nestin expression in normal liver or tumor samples.Nestin-driven GFP, whereas expression of the hepatocyte
markers CK8 and asialoglycoprotein receptor (HR) did not (Fig-
ure S2B). These observations reinforce the notion that, in
normal livers, Nestin is expressed in undifferentiated progenitor
cell populations.
To determine whether there was a direct relationship between
p53 and Nestin expression during liver tumorigenesis, we took
advantage of a liver carcinoma model that we previously used
to establish a role for p53 in tumor maintenance (Xue et al.,
2007). We isolated E12-15 liver progenitor cells (LPCs) from
fetal Nestin promoter-GFP mice and infected them with retrovi-
ruses coexpressing different oncogenes (H-RasG12D, Myc, or
YapS127A), each coupled to a tetracycline transactivator (tTA)that drives reversible shRNA expression. These vectors were
coexpressed with a second retrovirus containing a doxycy-
cline-regulated shRNA targeting p53 (schematized in Figure 3A).
Modified fetal liver cells were injected into livers of recipient
mice, and after tumor onset, the mice were fed a Doxycycline
(Dox)-containing diet to silence the shRNA and reactivate p53.
After 8 days, tumor tissue was isolated and analyzed for GFP
expression using immunoblotting of liver extracts or by immuno-
fluorescence of tissue sections.
Whereas the parental hepatoblast populations were negative
for GFP expression (data not shown), tumors with p53 depletion
(off-Dox) showed a strong GFP signal irrespective of the driving
oncogene, suggesting that p53 suppression derepressed theCell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc. 581
Figure 2. Nestin Expression Is Associated with Poor Prognosis and Correlates with p53 Loss of Function in Human HCCs
(A) Nestin mRNA expression in human liver cancer cell lines with intact p53 (p53WT) or loss of p53 function (p53mut/del).
(B) Nestin immunohistochemistry of normal liver tissue and HCC tissue. Scale bar, 50 mm.
(C) Survival analysis of liver cancer patients stratified into Nestin-positive and Nestin-negative groups.
(D) Nestin mRNA expression in human HCCs with p53 loss or diploid p53 status.
(E) Co-occurrence of nestin expression and p53 mutation in HCC samples. Fisher’s exact test was used for measuring association.
(F) Nestin expression and p53 expression in a wild-type-p53 expressing (p53+/+, left) and p53 mutant-expressing (p53R249S, right) tumor nodule of a multinodular
HCC. p53 mutation was determined by Sanger sequencing. Scale bars, 50 mm.
See also Figure S1 and Table S1.Nestin promoter or, alternatively, selected for a subset of cells
with intrinsically high Nestin levels. Consistent with the former
possibility, tumors re-expressing p53 following Dox addition
quickly silenced GFP (Figures 3B and 3C). Thus, p53 can repress
Nestin-promoter activity in vivo.582 Cell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc.p53 Regulates Nestin Expression in an
Sp-1/3-Dependent Manner
Studies suggest that p53 can act directly to repress mRNA tran-
scription by binding p53 response elements in target promoters
or can act indirectly by transcriptionally activating genes such as
Figure 3. Re-Expression of p53 Abolishes Nestin Expression In Vivo
(A) Schematic workflow of the generation of p53-regulatable liver tumors using Nestin promoter GFP hepatoblasts.
(B) GFP and p53 immunoblots from tumors of mice fed Dox-containing diet for 8 days or nomal chow.
(C) Immunofluorescence staining for GFP (green) and Nestin (red) of Ras;TREshp53 tumors off-Dox or 8 days on Dox. Scale bars, 200 mm.
See also Figure S2.p21,E2F7, andmiR-34 thatultimately reducemRNAlevels through
transcriptional or posttranscriptionalmechanisms (HoandBench-
imol, 2003). To assess the molecular basis for p53-mediated
Nestin repression in human HCC cell lines, we explored factors
that influenceNestin expression in humanHCCcell lineswithdele-
tion of p53 (Hep3B), harboring a Y220Cmutation in p53 (HuH7) or
expressing wild-type p53 (HepG2). Enforced expression of wild-
type p53 (p53WT) caused a substantial decrease in Nestin mRNA
(data not shown) and protein expression (Figure 4A) inHep3B cells
and HuH7 cells; conversely, suppression of wild-type p53 in
HepG2cells usingRNAicausedan increase inNestinprotein levels
(Figure 4A). Confirming the specificity of these effects, neither en-
forced expression of two different p53 mutants (R175H and
R248W) in p53 null Hep3B cells nor knockdown of mutant p53
(R249S) in PLC cells altered Nestin expression (Figure S3A).
Thus, p53 can repress Nestin in human HCC cells.
Using different informatics approaches, we identified a poten-
tial p53-binding site in the mouse Nestin gene (data not shown).
However, this site was not conserved in the human Nestin pro-
moter, and since p53 can suppress Nestin in human cells, we
hypothesized that p53 most likely represses Nestin through an
indirect mechanism. Still, its repressive effect was not mediated
through p21, E2F7, or miR-34 because Huh7 cells coexpressing
potent shRNAs targeting p21 or E2F7 still repressed Nestin
in response to wild-type p53 (Figure S3B), and no predicted
miR34-binding sites were found in the 30 UTR of the murine or
human transcripts (data not shown).Another mechanism whereby p53 can repress transcription is
by antagonizing other transcriptional activators. For example,
p53 can bind Sp1, leading to the repression of several Sp1-
inducible genes involved in embryonic development and angio-
genesis (Zhang et al., 2000). Interestingly, the murine Nestin
promoter harbors two Sp1-binding sites upstream of the tran-
scription start site (TSS), which are conserved in the human
Nestin gene and are crucial for Nestin expression (Cheng et al.,
2004) (see also Figure S3E). To test whether Sp1 (and its related
family member Sp3) controls Nestin in HCC cells, we used
siRNAs capable of knocking down either Sp1 or Sp3 and tested
their ability to modulate Nestin expression in p53 mutant HuH7
cells. Although none of the Sp1 and Sp3 siRNAs were capable
of potent Sp1/3 knockdown (Figure S3C), cosuppression of
both genes substantially reduced Nestin protein (Figure 4B)
and mRNA (Figure S3D) expression.
To investigate whether p53 influences the activity of the
Nestin promoter via Sp1, we transfected NIH 3T3 cells with mu-
rine Nestin promoter constructs harboring intact or mutated
Sp1-binding sites (Cheng et al., 2004) together with either a
p53WT expression vector or an empty vector control. Confirming
the Sp1 dependence of the Nestin promoter (Cheng et al.,
2004), cells transfected with reporter construct harboring intact
Sp1-binding sites (NESP 161/+183) showed luciferase activ-
ity, whereas cells harboring the construct with deleted Sp1 sites
(NESP DSp1) did not (Figure 4C). Importantly, coexpression
of p53 substantially decreased reporter output from theCell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc. 583
(legend on next page)
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NESP 161/+183 but had no effect on NESP DSp1 activity
(Figure 4C).
Chromatin immunoprecipitation (ChIP) experiments using an-
tibodies directed to either Sp1 or Sp3 revealed specific binding
of each protein to the consensus sites in p53 mutant human
HuH7 cells. Consistent with a role for p53 in modulating this
activity, enforced expression of wild-type p53 triggered a
release of Sp1 and Sp3 from the Nestin promoter (Figure 4D).
Similarly, treatment of Hep3B (p53 null) and Huh7 (p53
mutant) cells with mithramycin, a small molecule capable of
binding the GC-rich regions found in Sp1-binding sites (Bond
et al., 2004), abolished Sp1/3 binding to the Nestin promoter
in a dose-dependent manner (Figure 4E, F). Together, these
results indicate that Sp1 and Sp3 bind and activate the Nestin
promoter in HCC cells in a manner that is antagonized by func-
tional p53.
Wild-type p53 can interact directly with Sp1, suggesting a way
in which p53 might repress gene expression in a manner that is
disrupted in cancer cells. To confirm that this interaction can
occur in liver cancer cells, we cotransfected wild-type p53 into
p53 mutant HuH7 cells and assessed the ability of Sp1 to coim-
munoprecipitate with p53. Interestingly, the transduced wild-
type p53 bound Sp1, whereas the endogenous mutant p53 did
not (Figure S3F). Nonetheless, we could not detect p53 bound
to the Nestin promoter, suggesting that this interaction with
Sp1 occurs off chromatin (data not shown). p53/Sp1/3 com-
plexes have been reported to interfere with a self-amplification
process, leading to diminished Sp1/3 levels (Tapias et al.,
2008). Concordantly, we observed reduced Sp1, Sp3, and Nes-
tin protein levels in response to p53WT transduction into HuH7
cells (Figure S3G). Consistent with the role of Sp1/3 in activating
nestin, Nestin mRNA expression significantly correlated with
Sp1 levels in primary HCCs (Figure 4G) and Sp3 levels in CCs
(Figure 4H). Therefore, p53 represses Nestin at least in part by
antagonizing Sp1 and Sp3.
p53 Restricts Hepatocyte Transformation and Plasticity
To further investigate the relationship between p53 and Nestin
expression in liver tumorigenesis, we used a transposon-based
system that enables the production and analysis of liver carci-
nomas with defined genetic alterations in the mouse (Yant
et al., 2000). In this approach, plasmids harboring a recombinant
Sleeping Beauty (SB) transposon vector and transposase are in-Figure 4. p53 Regulates Nestin Expression in a Sp1/Sp3-Dependent M
(A) Nestin protein expression in Hep3B and HuH7 cells infected with a vector e
mediated p53 knockdown. p53 and p21 expression confirmed functional wild-ty
(B) Immunoblot for Nestin after siRNA knockdown of Sp1 and Sp3 in HuH7 cells
(C) Luciferase assay ofmurineNestin promoter constructs in the presence or abse
three independent experiments.
(D) ChIP analysis for Sp1 and Sp3 binding to theNestin promoter in the presence o
from three independent experiments.
(E) ChIP analysis for Sp1 and Sp3 binding to the Nestin promoter 18 hr after trea
indicated. Error bars correspond to pooled data from three independent experim
(F) Western blot analysis of Nestin expression in Hep3B and HuH7 cells 48 hr af
(G) Dot plot showing association of Nestin mRNA expression and Sp1 expressio
(H) Association of Nestin mRNA expression with Sp1, Sp3, and p53 mRNA expr
statistical significance.
See also Figure S3.jected into the liver using hydrodynamic tail-vein injection, which
leads to selective uptake by hepatocytes (Bell et al., 2007). Tran-
sient expression of transposase in the transduced hepatocytes
facilitates integration of the transposon vector into genomic
DNA, allowing stable and heritable transgene expression. Of
note, morphological and lineage-tracing studies indicate that
only differentiated hepatocytes and not cholangiocytes or pro-
genitor cells are transduced using this approach (Fan et al., 2012).
We chose to use Yap as a tumor-promoting oncogene, as it is
altered in both HCC and CC (Li et al., 2012) and can drive hepa-
tocellular carcinoma in orthotopic or transgenic models (Dong
et al., 2007; Zender et al., 2006). A two-vector system was
used to ensure the expression of Yap together with an shRNA
in the same cell: in one vector, Yap and a GFP reporter were
coexpressed under the control of the inducible TREtight (TREt)
promoter; in the other, the miR30 shRNA cassette was placed
downstream of a reverse tetracycline transactivator (rtTA3) ex-
pressed from the constitutive EF1a promoter (Figure 5A). Hence,
only cells receiving both vectors are capable of inducing Yap
expression upon Dox addition, and then these cells can be visu-
alized using the coexpressed GFP reporter. For these experi-
ments, we incorporated either a control shRNA targeting Renilla
firefly luciferase (shRen) or a well-characterized shRNA capable
of potently suppressing p53 (shp53).
Hydrodynamic tail-vein injection was used to target the above
vector combinations to the livers of FVBN mice. As anticipated
from previous reports (Fan et al., 2012), analysis of livers for
GFP-positive cells shortly after transduction identified the trans-
duced cells as HNF4a-expressing hepatocytes, and no trans-
duced cells were observed in CK19-positive cholangiocytes.
Similarly, injection of dsRed-expressing vectors into Nestin
promoter-GFP mice revealed no overlap of dsRed and Nestin
expression (Figure S4A). Six weeks after injection and Dox addi-
tion, mice receiving YAP and the control shRen transposons
showed no GFP fluorescence, suggesting that these cells were
eventually cleared. Accordingly, no overt pathology was ob-
served (Figures 5B and 5C, left). Thus, Yap alone was unable
to drive tumorigenesis over the observation period.
Livers from mice receiving the combination of Yap and a p53
shRNA displayed a dramatically different phenotype. Visual
inspection and histological analyses (Figures 5B and 5C, right)
revealed the presence of many GFP-positive foci consisting of
small undifferentiated tumor cells that displayed markers ofanner
xpressing p53WT or an empty vector (vector) and in HepG2 cells after RNAi-
pe p53 expression.
.
nce of wild-type p53 in NIH 3T3 cells. Error bars correspond to pooled data from
r absence of wild-type p53 in HuH7 cells. Error bars correspond to pooled data
tment with 1 mM Mithramycin or control (DMSO) in Hep3B and HuH7 cells as
ents.
ter Mithramycin treatment.
n in human HCCs, as determined by Spearman correlation.
ession in cholangiocarcinomas. Spearman correlation was used to determine
Cell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc. 585
Figure 5. Yap;shp53 Leads to Undifferentiated Nestin-Positive Tumors in Adult Hepatocytes
(A) Schematic of transposon vectors used in this experiment.
(B) Fluorescence images of whole livers 6 weeks after hydrodynamic transposon delivery into mice (n = 5).
(C) Representative H&E stainings of Yap;shp53 livers and Yap;shRen 6 weeks after injection. Scale bars, 100 mm.
(D) Nestin immunohistochemistry of liver sections from Yap;shp53-injected mice. Scale bars, 100 mm.
(E) Immunofluorescence of liver sections of Yap;shp53-injected mice. GFP marks expression of the YAP-containing transposon vector; Nestin expression is
detected by antibody staining. Scale bars, 50 mm.
See also Figure S4.bi-potential liver progenitors, having weak expression of the
epithelial marker CK19 and high expression of the stem cell
marker CD133 (data not shown). These tumors appeared
aggressive, showing numerous mitotic figures and invasive
growth (Figure 5C). Consistent with the ability of p53 to repress
Nestin, most Yap/shp53-expressing tumors were also Nestin
positive (Figures 5D and 5E). Importantly, similar tumors were
produced using an orthogonal approach whereby a cre-ER
transgene was substituted for the p53 shRNA and the same
experiment performed using p53-floxed mice (p53fl/fl) (Fig-
ure S4B): only animals treated with tamoxifen (to activate cre
and delete p53) developed tumors, all of which were GFP posi-
tive, undifferentiated, and highly expressed Nestin (Figures586 Cell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc.S4C–S4E). Together, these data demonstrate that p53 loss facil-
itates YAP-induced tumorigenesis by allowing dedifferentiation
of adult hepatocytes into progenitor-like cells capable of malig-
nant expansion. Thus, p53 appears to restrict cellular plasticity
in response to an oncogenic stimulus.
Nestin Is Required for Tumorigenesis
Although Nestin has been considered simply a marker of stem
and progenitor cells, its tight link to p53 expression in the liver
raised the possibility that it plays amore active role in tumorigen-
esis. To test this, we injected transposons encoding YAP and
p53 shRNA into murine livers together with an excess of a third
EF1a-driven transposon vector that coexpresses either a Nestin
Figure 6. Nestin Is Important for Tumor Initiation In Vivo
(A) Schematic of injected transposon vectors used in this experiment. Respective GFP and dsRED fluorescence images of livers from transposon-injected mice
6 weeks after injection (n = 5–7 mice per experiment), as indicated.
(B) H&E stainings of the livers. Scale bars, 100 mm.
(C) Quantification of tumor numbers of animals. Error bars represent SEM (n = 5–7 per group).
(D) dsRED expression in normal livers 6 weeks after injection of indicated transposon vectors.
See also Figure S5.or control (Renilla luciferase) shRNA with dsRED (Figure 6A).
Expression of Yap/p53shRNA was again traced using GFP,
whereas dsRED provided a surrogate marker for Nestin or
Renilla shRNA expression. These combinations were introducedinto mice by hydrodynamic transfection, and livers were
analyzed 6 weeks later.
The addition of the control dsRED-linked shRNA had no impact
on the disease course induced by the Yap/shp53 combination,Cell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc. 587
andmultipleGFP/dsREDdouble-positive tumorswith an undiffer-
entiated histology were detected in the livers of recipient mice
(Figures 6A and 6B). By marked contrast, the inclusion of two in-
dependent dsRED-linked Nestin shRNAs completely blocked tu-
mor formation, such that the recipient livers showed no dsRED/
GFP foci, and no tumors were identified by histology (Figure 6C).
The inhibitory effect of Nestin shRNAs on tumor formation was
not merely a toxic side effect of RNAi in hepatocytes (Grimm
et al., 2006), as mice receiving dsRED-linked Nestin shRNAs
without Yap and the p53 shRNA showed many dsRED-positive
cells thatwere retained in the liver for at least 6weekswithout pro-
ducing any overt liver pathology (Figure 6D and data not shown).
p53 mutant Huh7 cells transduced with two potent indepen-
dent Nestin shRNAs (Figure S5A) showed an accumulation of
cells in G2/M phase of the cell cycle (Figure S5C) and an increase
in phospho-H3-positive cells, indicative of impaired progression
through mitosis (Figure S5D). Accordingly, Nestin-depleted cells
were less able to form colonies when placed at low density (Fig-
ure S5B) and displayed decreased tumorigenic potential upon
injection into immunocompromised mice (Figure S5E). Although
these results indicated that nestin is necessary for tumorigenesis
of p53 mutant murine and human HCC cells, it is not sufficient:
hence, retroviral transduction of Nestin cDNA into myc;p53+/+
hepatoblasts was unable to mirror p53 loss in promoting
transformation and had no additional impact on the proliferative
capacity ofmyc;p53/ hepatoblasts in vitro (Figure S5F). There-
fore, Nestin is required for the dedifferentiation and malignant
expansion of p53-deficient cells and apparently contributes to
tumor maintenance.
Additional Oncogenic ‘‘Hits’’ Program p53-Deficient
Progenitor Tumors into HCCs or CCs
Although Nestin expression is normally restricted to a putative
stem/progenitor cell compartment in the liver, our results
demonstrate that deletion of p53 in hepatocytes facilitates
cellular plasticity in response to Yap, leading to the generation
of undifferentiated tumors with high Nestin expression. Nonethe-
less, tumors with a similar histology are not observed in humans,
perhaps because lesions that enforce lineage specification
cooperate with p53 loss during tumorigenesis. We therefore hy-
pothesized that these undifferentiated cells might be driven to
HCC or CC by enforcingWnt or Notch pathway activation, which
drive hepatocyte and cholangiocyte differentiation (Boulter et al.,
2012) and are frequently activated in HCC and CC, respectively.
To do this, we produced dsRED-tagged transposon vectors ex-
pressing anAPC shRNA, which deregulatesWnt signaling, or the
notch intracellular domain (NICD), which constitutively activates
Notch signaling, and performed hydrodynamic transduction with
the YAP/GFP and p53 shRNA transposons, as described above
(Figures 7A and 7D).
Histological analyses of the Yap/p53shRNA/APCshRNA-
transduced livers performed 6 weeks after injection contained
many epithelial tumors composed of polygonal cells growing in
a solid-trabecular pattern without a desmoplastic stroma—fea-
tures that are characteristic of HCC (Figure 7A). More detailed
microscopic analysis of the same tissue also revealed small un-
differentiated tumors similar to those observed in mice trans-
duced with just YAP and shp53 (Figure 7A, arrows). Interestingly,588 Cell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc.the HCC-like lesions showed coexpression of GFP and dsRED,
whereas undifferentiated tumor regions only expressed GFP,
indicating that they did not express shAPC (Figure 7B). In agree-
ment, the hepatocyte-specific marker HNF4a was expressed
in the GFP/dsRED-double-positive HCC-like tumor zones
and double-negative normal hepatocytes, but not in the GFP
single-positive undifferentiated tumors (Figure 7C). Regardless
of their differentiation state, all tumors expressed high Nestin
levels (Figure 7C). Thus, APC loss can drive p53-deficient
progenitor-like lesions toward those with features of hepatocyte
differentiation while retaining high Nestin expression.
Coexpression of NICD with Yap and shp53 produced a mark-
edly distinct result. Histopathological examination revealed
tumors that displayed the typical ductal and papillary growth
pattern and stromal involvement of CC (Figure 7D) and ex-
pressed GFP, mCherry, and the cholangiocyte marker HNF1b
(Figure 7E). Despite their differentiated phenotype but consistent
with CCs harboring mutant p53, these murine CCs retained high
Nestin expression (Figure 7E). Collectively, these results demon-
strate that p53, in part through repressing Nestin, restricts both
cell plasticity and tumorigenesis in the liver. As a consequence,
p53-deficient hepatocytes can produce tumors that adopt char-
acteristics of distinct cell fates depending on initiating and coop-
erating oncogenic events.
DISCUSSION
Many studies have focused on the activity of p53 as a transcrip-
tional activator and its target genes linked to cell-cycle arrest,
apoptosis, senescence, and other antiproliferative processes
(Vousden and Lane, 2007). Here, we demonstrate that p53 acts
via Sp1/3 to repress Nestin expression and that Nestin is
required for p53 inactivation to promote liver tumorigenesis.
Further, p53 loss enables dedifferentiation of mature hepato-
cytes in response to an oncogenic stimulus, leading to the
expansion of malignant reprogrammed progenitor cells that are
capable of acquiring features of HCC or CC upon acquiring line-
age-specific oncogenic lesions. Nonetheless, these tumors
retain high Nestin expression and an aspect of ‘‘stemness’’
that, in patients, is associated with a poor prognosis. Conse-
quently, our results identify Nestin as a key player in liver carcino-
genesis and have implications for p53 action in tumor
suppression.
Nestin Is a Stem Cell Marker that Functionally
Contributes to Liver Tumorigenesis
A direct role for Nestin in modulating liver cancer was unex-
pected, given its established role as a marker of stemness in
neural progenitor cells and malignant gliomas (Chen et al.,
2012; Mignone et al., 2004). Nonetheless, hints that Nestin plays
a broader role in normal stem cell biology and cancer come from
studies showing that nestin marks progenitor cell populations
outside of the central nervous system and that its inhibition
can impair the proliferation and survival of certain cancer cell
lines in culture (Krupkova et al., 2010). Though our data confirm
these observations for HCC, the molecular mechanism by which
Nestin contributes to liver tumorigenesis remains to be deter-
mined. Consistent with our observations, Nestin is required for
Figure 7. Progenitor Cells Can Differentiate to HCC or CC In Vivo
(A) Schematic of transposon vector combination used to generate HCCs and representative H/E stainings of tumors after 6 weeks. Arrows indicate small
progenitor tumor cells. Scale bar, 100 mm.
(B) GFP (Yap;shp53), dsRED (shAPC), HNF4a, and Nestin staining of progenitor-like tumor cells and HCC-like tumor cells. Scale bars, 200 mm.
(C) Immunofluorescence images of a tumor nodule of Yap/shp53/shAPC-injected mice. GFP indicates Yap/shp53, dsRED indicates shAPC, and HNF4a was
detected by Alexa-648 secondary antibody. DAPI was used for counterstaining. Scale bars, 100 mm.
(D) Schematic of transposon vectors used to generate CC and representative H/E sections of liver tumors 6 weeks after injection.
(E) GFP (Yap;shp53), mCherry (NICD), HNF1b, and Nestin immunohistochemistry of cholangiocarcinomas.
Scale bars, 100 mm.cell proliferation, migration, and invasion in other contexts, for
example, during neuronal cell development and in glioblastoma
and lung cancer cell lines (Lu et al., 2011; Sahlgren et al., 2006;
Takakuwa et al., 2013).
Because Nestin is not normally expressed in adult hepato-
cytes but is induced in response to oncogenic stress, the
requirement for Nestin in proliferation may reflect its ability to
promote cell reorganization after mitosis in rapidly proliferating
cells (Takakuwa et al., 2013). Accordingly, our limited analysis
confirms that Nestin is required for efficient progression through
the G2/M phase of the cell cycle in human HCC cells. Regardlessof the precise mechanism, our data indicate that Nestin is not
merely a stem/progenitor cell marker but, instead, actively par-
ticipates in cancer progression.
p53-MediatedGene Repression and Tumor Suppression
Our results have implications for the biochemical properties of
p53 that contribute to its action in cancer suppression. Despite
intensive efforts to prove its relevance, it remains unclear
whether transcriptional activation by p53 is sufficient to mediate
tumor suppression (Brady et al., 2011). In light of this conun-
drum, it is intriguing that p53 can also repress transcription,Cell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc. 589
and consistent with its importance, p53-mediated repression of
Nestin in the liver restricts cellular plasticity and limits tumorigen-
esis. Hence, p53 loss leads to high Nestin expression in p53
mutant tumors, and Nestin ablation impairs tumor formation.
p53 represses Nestin through an indirect mechanism that in-
volves its ability to bind Sp1 and impair its function. Whether
all p53 mutants are defective in binding Sp1 remains a topic of
debate, though there is general agreement that p53 mutations
disable its ability to repress Sp1 target genes (Zhang et al.,
2000). Interestingly, two other pluripotency genes—Nanog and
CD44—are also repressed by p53 (Godar et al., 2008; Lin
et al., 2005), hinting toward a broader role for p53-mediated
gene repression in maintaining cell identity. Although this repres-
sion is thought to result from direct p53 effects, both Nanog and
CD44 have functional SP1 sites in their promoters and could be
subject to SP1 antagonism by p53 as well (Wu and Yao, 2006;
Zhao et al., 2013). Beyond Nestin, p53/Sp1 represses the
expression of other genes, including VEGF, IGF-1R, and hTERT,
whose increased expression has been widely linked to tumori-
genesis. It thus seems likely that p53 limits tumor growth by
coordinating both gene activation and repression programs.
p53 Restricts Cellular Plasticity during Tumorigenesis
Our results also have ramifications for the biological properties of
p53 that contribute to tumor suppression. p53 loss in the liver
enables the aberrant expansion of oncogene-expressing cells.
Unexpectedly, those malignant cells that do emerge have high
nestin levels and thus retain some progenitor-like characteris-
tics, suggesting that these cells might be particularly sensitive
to the action of p53. Consistent with this view, p53 re-expression
in p53-deficient embryonic carcinoma cells triggers differentia-
tion (Lutzker and Levine, 1996), and p53 loss enables myeloid
progenitor cells to acquire an indefinite state of self-renewal in
response to certain oncogenic events, thereby contributing to
leukemogenesis. Together, these observations imply that a key
function of p53 in tumor suppression involves its ability to restrict
the self-renewal of multipotent progenitor cells. Indeed, the first
p53 function that was described was its ability to restrict cellular
immortalization (Harvey and Levine, 1991), a process character-
ized by the indefinite ability of cultured cells to self-renew.
Beyond limiting the ability of premalignant cells to self-renew,
our results imply that p53 can restrict their plasticity and that this
property is important for its action as a tumor suppressor.
Cellular plasticity is typically defined as the ability of cells to
change identity through a process of dedifferentiation, differen-
tiation, or both and contributes to regenerative processes in
plants, invertebrates, and amphibians (Sugimoto et al., 2011).
Emerging data suggest that a similar potential exists in mam-
mals, for example, as evidenced by the dedifferentiation of
luminal secretory cells into basal stem cells in the mouse lung
during injury repair (Tata et al., 2013). Indeed, recent studies in
mice suggest that dedifferentiation can accompany tumorigen-
esis and that differentiated cells can serve as the cell of origin
of cancer (Friedmann-Morvinski et al., 2012; Schwitalla et al.,
2013).
Using a transgenesis method that stably expresses genes in
adult hepatocytes, we found that p53 loss confers extraordinary
cellular plasticity during liver tumorigenesis. Specifically, p53590 Cell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc.suppression in hepatocytes allows dedifferentiation and the
emergence of Nestin-positive progenitor cell tumors in response
to Yap, an oncogene that is overexpressed in human HCC and
CC and can drive hepatocellular carcinoma in mice (Dong
et al., 2007). Remarkably, such p53-deficient tumors can reac-
quire features of differentiated hepatocytes or even cholangio-
cytes with the addition of lineage-specific lesions that deregulate
theWnt and Notch pathways, respectively. Importantly, p53 loss
alone confers no lineage bias per se but, instead, enables the
expansion of progenitor-like cells that take on distinct cell fates
through different cooperating genetic events.
Of the oncogene combinations that we analyzed, p53 loss was
unique in its ability to produce tumors with features of undifferen-
tiated progenitor cells. It seems likely that the appearance of
these lesions also involves specific functions of YAP, as p53-
deficient tumors driven by Myc or oncogenic K-ras acquire fea-
tures of HCC and CC, respectively (Saborowski et al., 2013).
Nonetheless, irrespective of the cooperating oncogene, the re-
sulting p53-deficient tumors acquire some progenitor-like char-
acteristics as indicated by high Nestin expression. Perhaps
these observations explain the association between p53 muta-
tions and the presence of stem cell signatures in certain human
cancers (Markert et al., 2011; Mizuno et al., 2010) and why HCC
andCC, which otherwise display distinct mutational landscapes,
each display high rates of p53 mutations (Nault and Zucman-
Rossi, 2011).
A role for p53 maintaining cell identity by restricting plasticity
during cancer is consistent with disparate observations relating
p53 biology to cellular differentiation and stem cell biology. A pri-
mordial role for p53 in controlling cell plasticity in vivo has been
noted during limb regeneration in the Salamander (Yun et al.,
2013). Despite little evidence that p53 contributes to normal
mammalian development, enforced p53 expression triggers dif-
ferentiation in certain p53-deficient tumor cells (Soddu et al.,
1994), and conversely, p53 loss has been described as a factor
that promotes dedifferentiation during glioblastoma develop-
ment in mice (Friedmann-Morvinski et al., 2012). Collectively,
these observations imply that p53 helps to maintain cell identity
in cells encountering aberrant proliferative signals and support
the emerging view that dedifferentiation can be important for
the etiology of certain tumor types.
Our results are particularly intriguing in light of p53 action in
limiting the epigenetic reprogramming of differentiated cells
into induced pluripotent stem (iPS) cells (Hong et al., 2009; Ka-
wamura et al., 2009; Mario´n et al., 2009). While demonstrating a
role for p53 in limiting plasticity, the cancer relevance of these
observations was unknown and indeed might merely reflect a
benefit due to increased proliferation in the reprogramming
process (Hanna et al., 2009). Our studies suggest that p53
loss enables the reprogramming of differentiated hepatocytes
to malignant progenitors with multilineage potential that can ac-
quire distinct cell fates through sustaining other mutations.
Though it seems likely that human liver carcinomas can arise
from normal progenitor cells as well, our studies establish the
importance of p53 in restricting cellular plasticity during liver
carcinogenesis and define a tumorigenic path for the emer-




The Nestin promoter-GFP mice were described before (Cheng et al., 2004).
Female, 8- to 10-week-old FVB/N mice were purchased from Charles River
laboratories or Jackson laboratory. p53 fl/fl mice were obtained from our
breeding colony and were maintained on a Bl6 background. The Alfp-Cre
p53 fl/fl animals were described recently (Katz et al., 2012). All animal experi-
ments were approved by the MSKCC Institutional Animal Care and Use Com-
mittee (protocol 11-06-011).
Hydrodynamic Tail-Vein Injection
For hydrodynamic tail-vein injection, a sterile 0.9% NaCl solution/plasmid mix
was prepared containing 10 mg DNA of each Transposon vector together with
CMV-SB13 Transpoase (1:5 ratio). Mice were injected with the 0.9% NaCl
solution/plasmid mix into the lateral tail vein with a total volume corresponding
10% of body weight in 5–7 s.
Human Patient Samples
Generation of mRNA and array-CGH data from human hepatocellular carci-
nomas (Neumann et al., 2012) and human cholangiocellular carcinomas (An-
dersen et al., 2012) was previously described. Pseudo-anonymized human
FFPE tissue samples from HCCs, HCC-CCCs, and CCCs were provided by
the Tissue Bank of the National Center for Tumor Diseases Heidelberg (Heidel-
berg, Germany) and the Institute of Pathology of the Greifswald University
(Greifswald, Germany). Institutional Review Board approval was obtained at
participating hospitals. All specimens were classified according to established
criteria (World Health Organization, Union for International Cancer Control) by
experienced pathologists (D.F.T., M.E., and T. L.).
Statistical Analysis
Data are presented as mean ± SD if not otherwise stated. The Spearman rank
coefficient or Fisher’s exact test were used for statistical measure of associa-
tion as indicted. The statistical comparison between two groups was accom-
plished with the two-tailed Student’s t test. All statistical tests were performed
using the PRISM6 software.
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doi.org/10.1016/j.cell.2014.05.051.
AUTHOR CONTRIBUTIONS
D.F.T. designed and performed the majority of experiments, withW.X., T.V.M.,
and L.Z. contributing key data and ideas important for the early stages of this
work. D.F.C., M.E., J.B.A., D.C., and T.L. analyzed human patient samples;
L.E.D., A.B., and E.R.K provided critical reagents and ideas; S.F.K. and A.L.
provided annotated tumor samples from Alfp-Cre p53fl/fl mice.; and S.W.
and C.-H.H. performed immunoprecipitation and chromatin immunoprecipita-
tion, respectively. G.E. provided the nestin-GFP mouse and G.E. and S.W.L.
helped conceive the study and supervised research. D.F.T. and S.W.L. wrote
the manuscript with the input of all coauthors.
ACKNOWLEDGMENTS
We thank all members of the Lowe lab for stimulating discussion and, in partic-
ular, Dr. Charles J. Sherr for important suggestions and editing themanuscript.
We thank D. Grace, J. Simon, the MSKCC animal facility, and MSKCC molec-
ular cytology core for outstanding technical support. This work was supported
by program project grants from the National Cancer Institute (S.W.L.). This
study was supported by the National Center for Tumor Disease, Heidelberg,
and grants of the German Research Foundation (DFG, SFB/TRR77) and the
German Cancer Aid (T.L.). D.F.T. is funded by a postdoctoral fellowship of
the German Research Foundation (DFG). S.W.L. is the Geoffrey Beene Chair
for Cancer Biology and a Howard Hughes Medical Institute investigator.Received: January 1, 2014
Revised: April 21, 2014
Accepted: May 27, 2014
Published: July 31, 2014
REFERENCES
Andersen, J.B., Spee, B., Blechacz, B.R., Avital, I., Komuta, M., Barbour, A.,
Conner, E.A., Gillen, M.C., Roskams, T., Roberts, L.R., et al. (2012). Genomic
and genetic characterization of cholangiocarcinoma identifies therapeutic tar-
gets for tyrosine kinase inhibitors. Gastroenterology 142, 1021–1031.e1015.
Bell, J.B., Podetz-Pedersen, K.M., Aronovich, E.L., Belur, L.R., McIvor, R.S.,
and Hackett, P.B. (2007). Preferential delivery of the Sleeping Beauty trans-
poson system to livers of mice by hydrodynamic injection. Nat. Protoc. 2,
3153–3165.
Bond, G.L., Hu, W., Bond, E.E., Robins, H., Lutzker, S.G., Arva, N.C., Bargo-
netti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004). A single nucleotide poly-
morphism in the MDM2 promoter attenuates the p53 tumor suppressor
pathway and accelerates tumor formation in humans. Cell 119, 591–602.
Boulter, L., Govaere, O., Bird, T.G., Radulescu, S., Ramachandran, P., Pelli-
coro, A., Ridgway, R.A., Seo, S.S., Spee, B., Van Rooijen, N., et al. (2012).
Macrophage-derivedWnt opposes Notch signaling to specify hepatic progen-
itor cell fate in chronic liver disease. Nat. Med. 18, 572–579.
Brady, C.A., Jiang, D., Mello, S.S., Johnson, T.M., Jarvis, L.A., Kozak, M.M.,
Kenzelmann Broz, D., Basak, S., Park, E.J., McLaughlin, M.E., et al. (2011).
Distinct p53 transcriptional programs dictate acute DNA-damage responses
and tumor suppression. Cell 145, 571–583.
Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G., and Parada,
L.F. (2012). A restricted cell population propagates glioblastoma growth after
chemotherapy. Nature 488, 522–526.
Cheng, L., Jin, Z., Liu, L., Yan, Y., Li, T., Zhu, X., and Jing, N. (2004). Charac-
terization and promoter analysis of the mouse nestin gene. FEBS Lett. 565,
195–202.
Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S.A.,
Gayyed, M.F., Anders, R.A., Maitra, A., and Pan, D. (2007). Elucidation of a
universal size-control mechanism in Drosophila and mammals. Cell 130,
1120–1133.
Fan, B., Malato, Y., Calvisi, D.F., Naqvi, S., Razumilava, N., Ribback, S., Gores,
G.J., Dombrowski, F., Evert, M., Chen, X., and Willenbring, H. (2012). Cholan-
giocarcinomas can originate from hepatocytes in mice. J. Clin. Invest. 122,
2911–2915.
Fellous, T.G., Islam, S., Tadrous, P.J., Elia, G., Kocher, H.M., Bhattacharya, S.,
Mears, L., Turnbull, D.M., Taylor, R.W., Greaves, L.C., et al. (2009). Locating
the stem cell niche and tracing hepatocyte lineages in human liver. Hepatology
49, 1655–1663.
Friedmann-Morvinski, D., Bushong, E.A., Ke, E., Soda, Y., Marumoto, T.,
Singer, O., Ellisman, M.H., and Verma, I.M. (2012). Dedifferentiation of neurons
and astrocytes by oncogenes can induce gliomas in mice. Science 338, 1080–
1084.
Gleiberman, A.S., Encinas, J.M., Mignone, J.L., Michurina, T., Rosenfeld,
M.G., and Enikolopov, G. (2005). Expression of nestin-green fluorescent pro-
tein transgene marks oval cells in the adult liver. Dev. Dyn. 234, 413–421.
Godar, S., Ince, T.A., Bell, G.W., Feldser, D., Donaher, J.L., Bergh, J., Liu, A.,
Miu, K., Watnick, R.S., Reinhardt, F., et al. (2008). Growth-inhibitory and tu-
mor- suppressive functions of p53 depend on its repression of CD44 expres-
sion. Cell 134, 62–73.
Grimm, D., Streetz, K.L., Jopling, C.L., Storm, T.A., Pandey, K., Davis, C.R.,
Marion, P., Salazar, F., and Kay, M.A. (2006). Fatality in mice due to over-
saturation of cellular microRNA/short hairpin RNA pathways. Nature 441,
537–541.
Hanna, J., Saha, K., Pando, B., van Zon, J., Lengner, C.J., Creyghton, M.P.,
van Oudenaarden, A., and Jaenisch, R. (2009). Direct cell reprogramming is
a stochastic process amenable to acceleration. Nature 462, 595–601.Cell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc. 591
Harvey, D.M., and Levine, A.J. (1991). p53 alteration is a common event in the
spontaneous immortalization of primary BALB/c murine embryo fibroblasts.
Genes Dev. 5 (12B), 2375–2385.
Ho, J., and Benchimol, S. (2003). Transcriptional repression mediated by the
p53 tumour suppressor. Cell Death Differ. 10, 404–408.
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M.,
Okita, K., and Yamanaka, S. (2009). Suppression of induced pluripotent
stem cell generation by the p53-p21 pathway. Nature 460, 1132–1135.
Hussain, S.P., Schwank, J., Staib, F., Wang, X.W., and Harris, C.C. (2007).
TP53 mutations and hepatocellular carcinoma: insights into the etiology and
pathogenesis of liver cancer. Oncogene 26, 2166–2176.
Katz, S.F., Lechel, A., Obenauf, A.C., Begus-Nahrmann, Y., Kraus, J.M., Hoff-
mann, E.M., Duda, J., Eshraghi, P., Hartmann, D., Liss, B., et al. (2012). Disrup-
tion of Trp53 in livers of mice induces formation of carcinomas with bilineal
differentiation. Gastroenterology 142, 1229–1239.
Kawamura, T., Suzuki, J., Wang, Y.V., Menendez, S., Morera, L.B., Raya, A.,
Wahl, G.M., and Izpisu´a Belmonte, J.C. (2009). Linking the p53 tumour sup-
pressor pathway to somatic cell reprogramming. Nature 460, 1140–1144.
Kenzelmann Broz, D., and Attardi, L.D. (2010). In vivo analysis of p53 tumor
suppressor function using genetically engineeredmousemodels. Carcinogen-
esis 31, 1311–1318.
Krupkova, O., Jr., Loja, T., Zambo, I., and Veselska, R. (2010). Nestin expres-
sion in human tumors and tumor cell lines. Neoplasma 57, 291–298.
Li, H., Wolfe, A., Septer, S., Edwards, G., Zhong, X., Abdulkarim, A.B., Ranga-
nathan, S., and Apte, U. (2012). Deregulation of Hippo kinase signalling in hu-
man hepatic malignancies. Liver Int. 32, 38–47.
Lin, T., Chao, C., Saito, S., Mazur, S.J., Murphy, M.E., Appella, E., and Xu, Y.
(2005). p53 induces differentiation of mouse embryonic stem cells by sup-
pressing Nanog expression. Nat. Cell Biol. 7, 165–171.
Lu,W.J., Lan, F., He, Q., Lee, A., Tang, C.Z., Dong, L., Lan, B., Ma, X.,Wu, J.C.,
and Shen, L. (2011). Inducible expression of stem cell associated intermediate
filament nestin reveals an important role in glioblastoma carcinogenesis. Int. J.
Cancer 128, 343–351.
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D.F., Bolden,
J.E., Zhao, Z., Thapar, V., Joyce, J.A., Krizhanovsky, V., and Lowe, S.W.
(2013). Non-cell-autonomous tumor suppression by p53. Cell 153, 449–460.
Lutzker, S.G., and Levine, A.J. (1996). A functionally inactive p53 protein in
teratocarcinoma cells is activated by either DNA damage or cellular differenti-
ation. Nat. Med. 2, 804–810.
Mario´n, R.M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-
Capetillo, O., Serrano, M., and Blasco, M.A. (2009). A p53-mediated DNA
damage response limits reprogramming to ensure iPS cell genomic integrity.
Nature 460, 1149–1153.
Markert, E.K., Mizuno, H., Vazquez, A., and Levine, A.J. (2011). Molecular clas-
sification of prostate cancer using curated expression signatures. Proc. Natl.
Acad. Sci. USA 108, 21276–21281.
Mignone, J.L., Kukekov, V., Chiang, A.S., Steindler, D., and Enikolopov, G.
(2004). Neural stem and progenitor cells in nestin-GFP transgenic mice.
J. Comp. Neurol. 469, 311–324.
Mizuno, H., Spike, B.T., Wahl, G.M., and Levine, A.J. (2010). Inactivation of p53
in breast cancers correlates with stem cell transcriptional signatures. Proc.
Natl. Acad. Sci. USA 107, 22745–22750.
Nault, J.C., and Zucman-Rossi, J. (2011). Genetics of hepatobiliary carcino-
genesis. Semin. Liver Dis. 31, 173–187.
Neumann, O., Kesselmeier, M., Geffers, R., Pellegrino, R., Radlwimmer, B.,
Hoffmann, K., Ehemann, V., Schemmer, P., Schirmacher, P., Lorenzo Ber-
mejo, J., and Longerich, T. (2012). Methylome analysis and integrative profiling
of human HCCs identify novel protumorigenic factors. Hepatology 56, 1817–
1827.
Roskams, T. (2006). Liver stem cells and their implication in hepatocellular and
cholangiocarcinoma. Oncogene 25, 3818–3822.592 Cell 158, 579–592, July 31, 2014 ª2014 Elsevier Inc.Rumsby, P.C., Davies, M.J., and Evans, J.G. (1994). Screening for p53 muta-
tions in C3H/He mouse liver tumors derived spontaneously or induced with di-
ethylnitrosamine or phenobarbitone. Mol. Carcinog. 9, 71–75.
Saborowski, A., Saborowski, M., Davare, M.A., Druker, B.J., Klimstra, D.S.,
and Lowe, S.W. (2013). Mouse model of intrahepatic cholangiocarcinoma
validates FIG-ROS as a potent fusion oncogene and therapeutic target.
Proc. Natl. Acad. Sci. 110, 19513–19518.
Sahlgren, C.M., Pallari, H.M., He, T., Chou, Y.H., Goldman, R.D., and Eriksson,
J.E. (2006). A nestin scaffold links Cdk5/p35 signaling to oxidant-induced cell
death. EMBO J. 25, 4808–4819.
Schwitalla, S., Fingerle, A.A., Cammareri, P., Nebelsiek, T., Go¨ktuna, S.I.,
Ziegler, P.K., Canli, O., Heijmans, J., Huels, D.J., Moreaux, G., et al. (2013).
Intestinal tumorigenesis initiated by dedifferentiation and acquisition of
stem-cell-like properties. Cell 152, 25–38.
Sekiya, S., and Suzuki, A. (2012). Intrahepatic cholangiocarcinoma can arise
from Notch-mediated conversion of hepatocytes. J. Clin. Invest. 122, 3914–
3918.
Soddu, S., Blandino, G., Citro, G., Scardigli, R., Piaggio, G., Ferber, A.,
Calabretta, B., and Sacchi, A. (1994). Wild-type p53 gene expression induces
granulocytic differentiation of HL-60 cells. Blood 83, 2230–2237.
Spike, B.T., andWahl, G.M. (2011). p53, Stem Cells, and Reprogramming: Tu-
mor Suppression beyond Guarding the Genome. Genes Cancer 2, 404–419.
Sugimoto, K., Gordon, S.P., and Meyerowitz, E.M. (2011). Regeneration in
plants and animals: dedifferentiation, transdifferentiation, or just differentia-
tion? Trends Cell Biol. 21, 212–218.
Takakuwa, O., Maeno, K., Kunii, E., Ozasa, H., Hijikata, H., Uemura, T., Kasai,
D., Ohkubo, H., Miyazaki, M., Oguri, T., and Niimi, A. (2013). Involvement of in-
termediate filament nestin in cell growth of small-cell lung cancer. LungCancer
81, 174–179.
Tapias, A., Ciudad, C.J., Roninson, I.B., and Noe´, V. (2008). Regulation of Sp1
by cell cycle related proteins. Cell Cycle 7, 2856–2867.
Tata, P.R., Mou, H., Pardo-Saganta, A., Zhao, R., Prabhu, M., Law, B.M., Vi-
narsky, V., Cho, J.L., Breton, S., Sahay, A., et al. (2013). Dedifferentiation of
committed epithelial cells into stem cells in vivo. Nature 503, 218–223.
Vousden, K.H., and Lane, D.P. (2007). p53 in health and disease. Nat. Rev.
Mol. Cell Biol. 8, 275–283.
Vousden, K.H., and Prives, C. (2009). Blinded by the Light: The Growing
Complexity of p53. Cell 137, 413–431.
Wu, D.Y., and Yao, Z. (2006). Functional analysis of two Sp1/Sp3 binding sites
in murine Nanog gene promoter. Cell Res. 16, 319–322.
Xue, W., Zender, L., Miething, C., Dickins, R.A., Hernando, E., Krizhanovsky,
V., Cordon-Cardo, C., and Lowe, S.W. (2007). Senescence and tumour clear-
ance is triggered by p53 restoration in murine liver carcinomas. Nature 445,
656–660.
Yant, S.R., Meuse, L., Chiu, W., Ivics, Z., Izsvak, Z., and Kay, M.A. (2000). So-
matic integration and long-term transgene expression in normal and haemo-
philic mice using a DNA transposon system. Nat. Genet. 25, 35–41.
Yun, M.H., Gates, P.B., and Brockes, J.P. (2013). Regulation of p53 is critical
for vertebrate limb regeneration. Proc. Natl. Acad. Sci. USA 110, 17392–
17397.
Zender, L., Spector, M.S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J.,
Fan, S.T., Luk, J.M., Wigler, M., Hannon, G.J., et al. (2006). Identification and
validation of oncogenes in liver cancer using an integrative oncogenomic
approach. Cell 125, 1253–1267.
Zhang, L., Yu, D., Hu, M., Xiong, S., Lang, A., Ellis, L.M., and Pollock, R.E.
(2000). Wild-type p53 suppresses angiogenesis in human leiomyosarcoma
and synovial sarcoma by transcriptional suppression of vascular endothelial
growth factor expression. Cancer Res. 60, 3655–3661.
Zhao, Y., Zhang, W., Guo, Z., Ma, F., Wu, Y., Bai, Y., Gong, W., Chen, Y.,
Cheng, T., Zhi, F., et al. (2013). Inhibition of the transcription factor Sp1 sup-
presses colon cancer stem cell growth and induces apoptosis in vitro and in
nude mouse xenografts. Oncol. Rep. 30, 1782–1792.
